Spruce Biosciences, Inc. - Common Stock (NQ:SPRB)

55.91 -3.05 (-5.18%)

Streaming Delayed Price Updated: 12:27 PM EDT, Sep 1, 2026 Add to My Watchlist

Price and Volume

Volume	28,808
Open	58.01
Bid (Size)	55.88 (100)
Ask (Size)	56.77 (100)
Prev. Close	58.97
Today's Range	55.70 - 58.05
52wk Range	7.260 - 240.00
Shares Outstanding	40,710,692
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Spruce Biosciences Announces Launch of MPS3BStudy.com

August 26, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Positive Pre-BLA Meetings with FDA and Confirms BLA Submission for TA-ERT on Track for Q4 2026

August 24, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Performance

YTD	-38.4%	-38.4%
1 Month	+29.6%	+29.6%
3 Month	+10.3%	+10.3%
6 Month	+3.2%	+3.2%
1 Year	+470.6%	+470.6%

More News

Spruce Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates

August 12, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Cure Sanfilippo Foundation and National MPS Society Make $5.5 Million Strategic Investment in Spruce Biosciences

August 12, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Jessica Cohen Pfeffer, M.D., as Vice President, Clinical Development

August 03, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Adrian Quartel, M.D., FFPM, as Chief Medical Officer

July 27, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Joins the Russell 3000® Index

June 29, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Agnieszka Jurecka, M.D., Ph.D., MPH, as Vice President, Medical Affairs

June 22, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Eric Jordan as Vice President, Marketing and Tina Gullotta as Vice President, Finance and Corporate Controller

June 15, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Long-Term Tralesinidase Alfa Enzyme Replacement Therapy Data in Sanfilippo Syndrome Type B (MPS IIIB) Presented at the 18th International MPS Symposium

June 08, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Data Presentation at the 18th International MPS Symposium

May 28, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in Upcoming Conferences in June

May 27, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates

May 13, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Further Strengthens its Commercial Leadership Team with the Appointments of Brian Walls as Vice President, Market Access and Darren Johnson as Vice President, Commercial Operations

May 04, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants

April 20, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

April 20, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Reports Full Year 2025 Financial Results and Provides Corporate Updates

March 09, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Appoints Dale Hooks, an Accomplished Rare Disease Commercial Leader, as Chief Commercial Officer

March 09, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Present at Upcoming Investor Conferences in March

March 02, 2026

From Spruce Biosciences, Inc.

Via Business Wire

SPRB Stock Drops After Company Pushes Back Application Submission Timeline For Experimental Sanfilippo Syndrome Therapy ↗

February 18, 2026

Via Stocktwits

Spruce Biosciences Announces Positive Type B Meetings with U.S. FDA for TA-ERT for the Treatment of Sanfilippo Syndrome Type B (MPS IIIB)

February 18, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences to Participate in the Oppenheimer 36th Annual Healthcare Life Sciences Conference

February 17, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Long-Term Data Presented at the 22nd Annual WORLDSymposium™ Highlights Tralesinidase Alfa Enzyme Replacement Therapy’s Potential as the First Disease-Modifying Treatment Option for Sanfilippo Syndrome Type B (MPS IIIB)

February 05, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Adds Regulatory and Clinical Development Expertise to Leadership Team

February 03, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Spruce Biosciences Announces Data Presentations at the 22nd Annual WORLDSymposium™

January 28, 2026

From Spruce Biosciences, Inc.

Via Business Wire

Frequently Asked Questions

Is Spruce Biosciences, Inc. - Common Stock publicly traded?

Yes, Spruce Biosciences, Inc. - Common Stock is publicly traded.

What exchange does Spruce Biosciences, Inc. - Common Stock trade on?

Spruce Biosciences, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Spruce Biosciences, Inc. - Common Stock?

The ticker symbol for Spruce Biosciences, Inc. - Common Stock is SPRB on the Nasdaq Stock Market

What is the current price of Spruce Biosciences, Inc. - Common Stock?

The current price of Spruce Biosciences, Inc. - Common Stock is 55.91

When was Spruce Biosciences, Inc. - Common Stock last traded?

The last trade of Spruce Biosciences, Inc. - Common Stock was at 09/01/26 12:27 PM ET

What is the market capitalization of Spruce Biosciences, Inc. - Common Stock?

The market capitalization of Spruce Biosciences, Inc. - Common Stock is 2.28B

How many shares of Spruce Biosciences, Inc. - Common Stock are outstanding?

Spruce Biosciences, Inc. - Common Stock has 2B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.